Phase I Study of the Antiangiogenic Antibody Bevacizumab and the mTOR/Hypoxia-Inducible Factor Inhibitor Temsirolimus Combined with Liposomal Doxorubicin: Tolerance and Biological Activity
Moroney, J., Fu, S., Moulder, S., Falchook, G., Helgason, T., Levenback, C., Hong, D., Naing, A., Wheler, J., Kurzrock, R.Volume:
18
Language:
english
Journal:
Clinical Cancer Research
DOI:
10.1158/1078-0432.ccr-12-1158
Date:
October, 2012
File:
PDF, 305 KB
english, 2012